Program
Wednesday, September 14th, 2022
08:30 // Registration and coffee
09:00 // Welcome
09:15 // SESSION 1: Will molecular tests enable sustainable precision medicine?
Chair: Kristin Austlid Taskén, Oslo University Hospital (NO)
09:15 // Genomics/PARP-I in Prostate Cancer: What, when and who
Maha Hussain, Northwestern University Feinberg School of Medicine (US)
09:45 // Will biomarkers - other than PSA - be used to guide treatment of advanced prostate cancer?
Nicolas Mottet, University Hospital St. Etienne and University Jean Monnet (FR)
10:15 // How cost-effective are biomarkers?
Derya Tilki, Martini-Klinik Prostate Cancer Centre, Hamburg (DE)
10:45 // The biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C, and
possibilities for their clinical implementation (selected from submitted abstracts)
Pernilla Wikström, Umeå University, Umeå (SE)
11:00 // Break
11:30 // SESSION 2: Providing evidence for implementing molecular tests in clinical guidelines
Chair: Rolf Skotheim, Oslo University Hospital (NO)
11:30 // Requirements for implementation of molecular tests into guidelines
Himisha Beltran, Dana-Farber Cancer Institute and Harvard Medical School (US)
Dentist Olaf Aase and wife memorial lecture
12:00 // Extracellular vesicles - from lab to clinical implementation
Jason M Alter, Exosome Diagnostics (US)
12:30 // Cribriform growth pattern with a high Ki-67 represents a subgroup of prostate cancer patients with a
particularly poor prognosis (selected from submitted abstracts)
Ulrika Axcrona, Oslo University Hospital, Oslo (NO)
12:40 // Spatial transcriptomics reveals biomarker SFRP4 to be strongly associated with extracellular matrix
remodeling in prostate cancer stroma (selected from submitted abstracts)
Maria Karoline Andersen, Norwegian University of Science and Technology, Trondheim (NO)
13:00 // Lunch
14:00 // Biomarker-driven precision medicine in Norway - where we are and where to go
Hege Russnes, Oslo University Hospital (NO)
14:15 // How to bring molecular tests into the clinic in Scandinavia
Henrik Grönberg, Karolinska Institutet and Capio S:t Göran Hospital (SE)
14:45 // Break
15:00 // Panel Discussion (in Norwegian)
- How and when can molecular tests provide sustainable precision medicine in the clinic?
Moderator Elisabeth Kirkeng Andersen (NO)
16:00 // Poster session
17:00 // Social activities (Munch museum, sauna, walk)
19:30 // Dinner (including Poster Awards) at Vaaghals
Thursday, September 15th, 2022
09:00 // SESSION 3: Precision medicine: impact of the tumour microenvironment
Chair: Heidi Lyng, Oslo University Hospital (NO)
09:00 // Everything in balance? Metabolism reprograms cells
Ian Mills, University of Oxford, Queen’s University of Belfast and University of Cambridge (UK)
09:30 // Hypoxia and subclonal evolution
Rob Bristow, Manchester Cancer Research Centre, CRUK Major research Centre, University of Manchester (UK)
10:00 // How can we move forward with immunotherapy in prostate cancer?
Johanna Olweus, Oslo University Hospital (NO)
10:15 // Break
10:45 // Discovery and testing of biomarkers and drugs in ex vivo and in vivo model systems
Wytske van Weerden, Erasmus Medical Center (NL)
11:15 // Biomarker potential of tumor hypoxia
Heidi Lyng, Oslo University Hospital (NO)
11:30 // Lunch
12:30 // Reversing off-target prostate cancer resistance
Mark Rubin, University of Bern (CH)
13:00 // Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1
Retrotransposition as a Dynamic Source of Cancer Heterogeneity (selected from submitted abstracts)
Kirsi Ketola, University of Eastern Finland, Kuopio (FI)
13:10 // Phenotypic deconvolution in heterogeneous cancer cell populations using drug screening data
(selected from submitted abstracts)
Even Moa, University of Oslo, Oslo (NO)
13:20 // SESSION 4: Pitfalls and opportunities in biomarker discovery
Chair: Alicia Llorente, Oslo University Hospital (NO)
13:20 // Functional and spatial precision cancer medicine
Olli Kallioniemi, Karolinska Institutet (SE)
13:50 // Break
14:20 // Exploring precision oncology: From gene fusions to lncRNAs
Arul Chinnaiyan, Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)
14:50 // Multifocal prostate cancer and implications for precision oncology
Rolf Skotheim, Oslo University Hospital (NO)
15:05 // Analysis of urinary extracellular vesicles form the discovery of prostate cancer biomarkers
Alicia Llorente, Oslo University Hospital (NO)
15:20 // European network for biomarker validation
Guido Jenster, Erasmus Medical Centre (NL)
16:00 // Closing remarks
Sponsors
